@Smester07 @Catherine_Muzo @BebetoDice @Mr_Jeffry
Le dan a PDF Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study | SpringerLink https://t.co/u8BNkphi8R
RT @VenkataPrabhak5: Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective…
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study | SpringerLink https://t.co/eyvBYImCFb
RT @aakonc: MSKCC group has been excluding intact GI/GU primary from riva, giving it everyone else. This may be way to go for now while awa…
MSKCC group has been excluding intact GI/GU primary from riva, giving it everyone else. This may be way to go for now while awaiting guidelines recs https://t.co/Mhzo8oNSI5
@GBarnesMD Results c/w "real world" data so assure ext validity https://t.co/Mhzo8oNSI5